

University of Dundee

Beta-blockers in COPD

Lipworth, Brian; Wedzicha, Jadwiga; Devereux, Graham; Vestbo, Jørgen; Dransfield, Mark T.

Published in:
European Respiratory Journal

DOI:
[10.1183/13993003.01847-2015](https://doi.org/10.1183/13993003.01847-2015)

Publication date:
2016

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Lipworth, B., Wedzicha, J., Devereux, G., Vestbo, J., & Dransfield, M. T. (2016). Beta-blockers in COPD: time for reappraisal. *European Respiratory Journal*, 48(3), 880-888. <https://doi.org/10.1183/13993003.01847-2015>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Beta-blockers in COPD: time for reappraisal

Journal:	<i>European Respiratory Journal</i>
Manuscript ID	ERJ-01847-2015.R2
Manuscript Type:	Review
Date Submitted by the Author:	23-May-2016
Complete List of Authors:	Lipworth, Brian; University of Dundee, Asthma & Allergy Research Group Wedzicha, Jadwiga; Imperial College London, Airways Disease Section, National Heart and Lung Institute Devereux, Graham; University of Aberdeen, Applied Health Sciences Vestbo, Jørgen; University of Manchester, Centre for Respiratory Medicine and Allergy Dransfield, Mark; University of Alabama at Birmingham, Pulmonary, Allergy and Critical Care
Key Words:	COPD, beta-blocker, coronary artery disease, heart failure, Exacerbations

SCHOLARONE™
Manuscripts

This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for publication in the European Respiratory Journal, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the copyright owner, the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication.

Beta-blockers in COPD: time for reappraisal

Authors: Dr Brian Lipworth¹, Prof Jadwiga Wedzicha², Prof Graham Devereux³,
Professor Jørgen Vestbo⁴, Dr Mark T. Dransfield⁵

Affiliations: ¹Scottish Centre for Respiratory Research, Ninewells Hospital and
Medical School, University of Dundee, Scotland, UK, ²Airways Disease
Section, National Heart & Lung Institute, Imperial College London, London, UK,
³Applied Health Sciences, University of Aberdeen, Aberdeen, UK, ⁴Centre for
Respiratory Medicine and Allergy, University Hospital South Manchester NHS
Foundation Trust, University of Manchester, UK, ⁵Lung Health Center, Division of
Pulmonary, Allergy and Critical Care Medicine, University of Alabama at
Birmingham, Alabama, USA; Birmingham VA Medical Center, Alabama, USA

Correspondence: Dr Brian Lipworth, Scottish Centre for Respiratory Research,
Ninewells Hospital & Medical School, University of Dundee, Dundee, DD1 9SY
b.j.lipworth@dundee.ac.uk

Manuscript word count: 3141

Author contributions: All authors contributed to the literature search, writing and
presentation of the manuscript, and approval of the final version.

“Take Home” message:

Beta-blockers (BB) are used for heart failure and after myocardial infarction but remain underused in COPD despite recommendations in guidelines.

Abstract

The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovascular burden in COPD. The use of beta-blockers in COPD has been proposed because of their known cardio-protective effects as well as reducing heart rate and improving systolic function. Despite the proven cardiac benefits of beta-blockers post myocardial infarction and in heart failure they remain underused due to concerns regarding potential bronchoconstriction even with cardio-selective drugs. Initiating treatment with beta-blockers requires dose titration and monitoring over a period of weeks, and beta-blockers may be less well tolerated in older patients with COPD who have other comorbidities. Medium term prospective placebo controlled safety studies in COPD are warranted to reassure prescribers regarding the pulmonary and cardiac tolerability of beta-blockers as well as evaluating their potential interaction with concomitant inhaled long acting bronchodilator therapy. Several retrospective observational studies have shown impressive reductions in mortality and exacerbations conferred by beta-blockers in COPD. However, this requires confirmation from long term prospective placebo controlled randomized controlled trials. The real challenge is to establish whether beta-blockers confer benefits on mortality and exacerbations in all patients with COPD including those with silent cardiovascular disease where the situation is less clear.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key words: COPD, beta-blocker, coronary artery disease, heart failure, exacerbations

Abstract word count: 198

Introduction

Chronic obstructive pulmonary disease (COPD) is one of the world's leading causes of morbidity and is now the third leading cause of mortality amounting to 3 million deaths in 2010.[1, 2] Exacerbations in particular account for up to three quarters of the total costs due to COPD,[3] with attributable costs exceeding 30 billion USD.[4] A recent COPD taskforce statement [5] identified an unmet need in terms of finding drugs to treat common co-morbidities specifically mentioning the putative effects of beta-blockers on the cardiovascular burden and its associated impact on mortality. Cardiovascular comorbidity is common in patients with COPD due to smoking in addition to other shared risks including genetic susceptibility, systemic inflammation and ageing.[6] The prevalence of COPD in patients with heart failure ranges from 11-52% in North American patients and 9-41% in European patients.[7] The purpose of this article is to critically reappraise the current knowledge regarding beta-blockers in COPD looking at the current evidence for their therapeutic index and how this relates to management guidelines.

We have not attempted a systematic review or meta-analysis as described elsewhere,[8-10] but rather highlighted the key areas of clinical relevance for physicians who treat patients with COPD. In this article we have 1) considered the putative link between COPD and the heart in terms of potential targets for beta-blockers, 2) reviewed retrospective data linking use of beta-blockers to reduced exacerbations and mortality, 3) examined the unmet need for use of beta-blockers in patients with COPD and both known, and potentially unknown cardiovascular disease, 4) evaluated which beta-blocker to use based on their pharmacology and

1
2
3 impact on pulmonary function, and 5) attempted to draw conclusions about the
4
5 current clinical use of beta-blockers in COPD.
6
7
8
9

10
11 **COPD and the heart (Figure 1 and Box 1)**
12

13 The main accepted clinical indications for the use of beta-blockers in COPD are for
14
15 patients post myocardial infarction and for patients with heart failure. However, the
16
17 presence of untreated or unrecognized (i.e. silent) cardiovascular disease may
18
19 contribute to mortality in COPD and may also be an underlying causative factor in
20
21 exacerbations which can be difficult to separate from respiratory etiologies.[6] [7] It is
22
23 also possible, if not likely, that the burden of cardiovascular disease may be under-
24
25 rated by pulmonologists when treating COPD patients because symptoms are
26
27 presumed to be primarily driven by airflow obstruction, especially during
28
29 exacerbations.
30
31

32 The prevalence of left ventricular systolic dysfunction ranges between 10-46% in
33
34 patients with COPD and though the occurrence of heart failure with preserved left
35
36 ventricular ejection fraction is less clear, estimates in patients with severe COPD are
37
38 as high as 90%.[7] The benefits of beta-blockers in patients with heart failure due to
39
40 left ventricular systolic dysfunction are well established from pivotal trials as well as
41
42 meta-analysis.[21-24] The challenge in COPD may be more with respect to
43
44 diagnosis of heart failure with echocardiography where image acquisition is difficult
45
46 due to lung hyperinflation.[25]
47
48
49

50 Beta-blockers only have proven benefits in patients post myocardial infarction but not
51
52 in stable coronary arterial disease.[11, 12] Nevertheless, the presence of coronary
53
54 calcium on chest CT scans is associated with mortality in COPD,[13] and known
55
56 coronary arterial disease is also associated with longer exacerbations, more
57
58
59
60

dyspnoea, lower health status and exercise capacity in stable patients with COPD.[14] There is also an acute increase in arterial stiffness particularly during infective exacerbations of COPD, along with increases in cardiac enzymes especially in patients with coronary arterial disease;[15] one study found that one in twelve patients admitted to hospital with an exacerbation of COPD met the criteria for a myocardial infarction.[16] The presence of coronary heart disease in COPD along with the adverse effects of hypoxaemia [17] may be compounded by the positive chronotropic effects of concomitant inhaled beta-agonist therapy,[18, 19] further compromising cardiac reserve. It has been shown that even a low dose of a beta-1 selective antagonist such as atenolol might protect against chronotropic, inotropic and electrocardiographic effects of inhaled beta-agonists which are mediated by cardiac beta₂ receptor stimulation.[20]

Another potential target is diastolic dysfunction though a meta-analysis suggests that the beneficial effects of beta-blockers in such patients are less clear cut.[26] Several factors may contribute to the occurrence of impaired diastolic function in COPD.

Firstly, patients with COPD also appear to have a higher left ventricular mass (hypertrophy) even in the absence of left ventricular dilatation. Secondly, lung hyperinflation in COPD may cause cardiac compression reducing both left ventricular and atrial filling even in the absence of raised pulmonary arterial pressure.[28-30]

These factors, may also be compounded by the negative effects of hypoxaemia on diastolic filling.[31] [17]

In addition to these COPD related risks, patients with the disease commonly have other co-morbidities such as coronary artery disease, hypertension and diabetes, which can all adversely affect diastolic function. This was addressed in a recent prospective longitudinal study of healthy young adults followed over 25 years, where

a fall in the ratio of forced expiratory volume in one second to forced vital capacity (FEV₁/FVC) was associated with reduced left atrial size and cardiac output.[32] Left ventricular end diastolic and end systolic wall stress measured by magnetic resonance imaging (MRI) is associated with increasing severity of airflow obstruction in patients with COPD and coexistent heart failure.[33] Impaired left ventricular filling is clinically important because it can eventually produce left atrial enlargement which is a key risk factor for atrial fibrillation and associated mortality during exacerbations of COPD.[34] Furthermore, the presence of impaired diastolic filling in patients with COPD is also related to impaired walking distance.[35] Thus, the absence of benefits of beta-blockers in diastolic dysfunction may not apply in COPD and deserved re-evaluation in this patient group.

Effects of beta-blockers on mortality and exacerbations

Due to the high cardiovascular comorbidity in COPD from smoking along with increased sympathetic drive due to hypoxaemia,[36] beta-blockers have been proposed as a cogent therapeutic intervention for their known cardio-protective effects in addition to reducing heart rate and improving systolic and diastolic dysfunction. One of the fundamental issues with regards to more widespread use of beta-blockers in COPD is the concern regarding beta₂ receptor antagonism and associated airway smooth muscle constriction which may even occur with cardio-selective agents which exhibit preferential beta₁ blockade, especially in more susceptible severe patients with impaired respiratory reserve. The risk-benefit equation in COPD becomes more favorable for patients who already have overt cardiac disease such as heart failure or post myocardial infarction, where beta-blockers have proven protective effects.[11, 21] There are, however, no data as to

the putative beneficial effects of beta-blockers in those COPD patients who may have concomitant silent coronary arterial disease or heart failure.

Retrospective observational data have shown beneficial effects of beta-blockers in a cohort of 5977 patients with COPD who were followed over a mean of 4.35 years [37] where their use was associated with an overall 22% (95% confidence interval 8-33) reduction in mortality. In a study of 825 patients admitted to hospital for an exacerbation of COPD, beta-blocker use among 142 patients was associated with a 61% (1-86) reduction in mortality.[38] Rutten et al showed 32% (17-44) and 29% (17-40) reductions in mortality and exacerbations, respectively, conferred by taking beta-blockers among 2230 patients with COPD followed up for a mean of 7.2 years.[39] In a cohort study from Sweden of 4858 patients with COPD, those who were discharged on a beta-blocker (84%) post myocardial infarction had 13% (2-22) lower mortality.[40] In a retrospective report of 256 patients with COPD with either coronary heart disease or heart failure, 58% were taking beta-blockers where there was a 73% (50-85) reduction in the likelihood of being admitted to a hospital emergency room.[41] In contrast, in an observational study using time dependent analysis of 2249 severe oxygen dependent COPD patients there was a 19% increase in mortality associated with taking beta-blockers.[42] However, in a prospectively followed cohort of 3464 patients Bhatt et al found a 27% (10-40) reduction in total exacerbations, while in GOLD 3/4 patients on home oxygen there was a 67% reduction (42-81).[43]

In a 2012 meta-analysis of 9 retrospective cohort studies, the pooled estimate for mortality reduction with beta-blockers was reported to be 31% (22-38).[8] In a subsequent 2014 meta-analysis of 15 retrospective studies of 21,596 patients with COPD, the pooled estimate for reduction in overall mortality conferred by beta-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

blockers was 28% (17-37) and for exacerbations was 38% (18-58).[9] The reduction in mortality was 36% (24-46) among the subgroup of patients (5 studies: 39% weighting) with known coronary heart disease and 26% (7-42) in the subgroup with known heart failure (3 studies: 18% weighting).

The beneficial effects of beta-blockers on exacerbations may involve other potential non-cardiac mechanisms whereby beta-blockers could reduce COPD exacerbations. In heart failure, use of cardioselective beta-blockers reduces systemic inflammatory cytokine release such as IL-6 and alters leukocyte distribution which may also impact inflammation during respiratory infections.[44] Beta-blockers have also been reported to inhibit neutrophil chemotaxis and oxygen free radical production,[45] while in human endothelial cells they have been reported to reduce the release of endothelin-1, a bronchoconstrictor peptide implicated in the pathogenesis of COPD exacerbations.[46, 47]

It is not possible to eliminate the possibility of residual confounding in the observational studies suggesting beta-blockers may reduce exacerbations and mortality in COPD and thus definitive randomized trials are needed. There is now a planned placebo controlled trial powered for a reduction in exacerbations using metoprolol over 1 year via the US COPD Clinical Research Network and funded by the Department of Defense (Clinicaltrials.gov Identifier:NCT02587351).

This study will only exclude those patients with an absolute indication for beta-blockers including an MI or revascularization procedure within three years or with an ejection fraction <40%. However, it remains possible that this and similar studies may run the risk of only including patients where beta-blockers are less efficacious.

The unmet cardiac need in COPD

Beta-blockers have an established position in the management of coronary artery disease while heart failure guidelines reinforce their use in patients with concomitant COPD.[51] Similarly, COPD management strategies also state that the benefits of selective beta-1 blocker treatment in heart failure clearly outweigh any potential risk associated with treatment even in patients with severe COPD.[52] Despite this guidance there is a reluctance to prescribe even cardio-selective beta-blockers in COPD, even in the presence of known cardiac disease because of persistent concerns regarding potential bronchoconstriction, especially in more severe patients. In a cohort from Scotland we found that only 14% of patients with COPD were taking beta-blockers for cardiovascular comorbidity.[37] Further evidence of a reluctance to prescribe beta-blockers in COPD was documented by Quint et al where 55% of patients who had a myocardial infarction were not prescribed a beta-blocker, with only 22% being prescribed on admission.[53] In the UK 64% of patients without COPD and acute coronary syndrome were prescribed beta-blockers as compared to 16% of similar patients with COPD who were prescribed beta-blockers.[54] Furthermore COPD was documented as a reason for withholding beta-blockers in 33% of patients who did not receive a beta-blocker, while non-cardiologists were 40% less likely to prescribe beta-blockers. In the United States, Chen et al found that elderly patients after an acute myocardial infarction were 62% less likely to be given beta-blockers in the presence of a history of treated COPD or asthma.[55] Initiating treatment with beta-blockers is not simple as it requires dose titration over a period of weeks along with monitoring of heart rate, blood pressure and perhaps spirometry, all of which take time, incurring extra healthcare costs. Moreover beta-blockers may be less well tolerated in older patients with co-existing comorbidities such as

diabetes, peripheral vascular disease and renal impairment, who are more prone to postural hypotension.

Choice of beta-blocker and effects on pulmonary function (Box 2)

The mechanism of beta-blocker induced bronchoconstriction is thought to be due to the effects of pre and post-junctional beta₂ receptor antagonism uncovering the prevailing cholinergic tone via post-junctional smooth muscle muscarinic type 3 receptors, resulting in airway smooth muscle constriction.[57]

In a subgroup analysis of 2712 patients from the Tayside cohort who had serial spirometry measures over 4 years, there was no deleterious effect of long term beta-blocker use (88% were cardioselective) on either FEV₁ or FVC, even among the more severe patients taking triple inhaled therapy, who had the greatest reductions in exacerbations and mortality.[37] In a meta-analysis of randomized controlled trials with cardio-selective beta-blockers there was no significant change in FEV₁ compared to placebo, when given either as single -2.1% (-6.1-2.0) or chronic dosing -2.6% (-5.9-0.8), and also no significantly effect on the FEV₁ response to beta₂-agonists[10]. In a randomized controlled trial of 27 patients with heart failure who also had coexistent moderate to severe COPD, after 4 months of treatment there was a 190ml significant fall FEV₁ between bisoprolol and placebo, while salbutamol reversibility, symptoms and quality of life were unchanged.[60] In a comparison of bisoprolol and placebo in patients with moderate to severe COPD, there was a significantly worsening of dynamic hyperinflation during cycle endurance while exercise duration was unaltered.[61] In a study comparing 24 COPD patients on beta-blockers matched to patients not taking beta-blockers there was no difference

1
2
3 in exercise capacity or gas exchange despite lower heart rate and blood pressure, in
4
5 turn suggesting great oxygen delivery per heart beat.[62]

6
7 The beta-blockers currently licensed for heart failure are the β_1 selective
8
9 bisoprolol, nebivolol, metoprolol and the non-selective carvedilol. As has already
10
11 been shown in heart failure [63] and asthma [49] it is important to slowly titrate up the
12
13 dose of beta-blocker to improve cardiovascular and pulmonary tolerability. Bisoprolol
14
15 has a licensed indication for use in heart failure and coronary artery disease and has
16
17 a $\beta_{1/2}$ receptor selectivity ratio of 14:1, which is higher than either atenolol (5:1) or
18
19 metoprolol (2:1).[64] In a cross-over study of 51 patients with COPD and heart
20
21 failure, directly comparing 6 weeks of bisoprolol, metoprolol and carvedilol,[65] FEV₁
22
23 was lowest with carvedilol and highest with bisoprolol with metoprolol in between. In
24
25 a randomized controlled trial comparing bisoprolol (mean dose 6.4mg) and carvedilol
26
27 (mean dose 47mg) in patients with heart failure and COPD, FEV₁ significantly
28
29 improved by 137ml with bisoprolol but not with carvedilol (30ml improvement).[66] In
30
31 15 mild to moderate COPD patients there was a significant worsening in airway
32
33 hyper-reactivity to methacholine challenge with metoprolol and propranolol but not
34
35 celiprolol compared to placebo, while the acute bronchodilator response to fenoterol
36
37 was only blunted by propranolol.[67]

38
39 Nebivolol has been shown to exhibit greater in vitro $\beta_{1/2}$ receptor selectivity than
40
41 bisoprolol in human myocardium.[68] In healthy volunteers attenuation of β_2
42
43 receptor mediated terbutaline induced hypokalaemia was significantly greater with
44
45 bisoprolol 10mg or atenolol 50mg/100mg verses nebivolol 5mg, which in turn was
46
47 not different from placebo.[69] Nebivolol produced significant blunting of terbutaline
48
49 induced glucose and insulin responses compared to placebo in keeping with β_2
50
51 receptor antagonism at the 5mg dose. However the relative $\beta_{1/2}$ selectivity cannot
52
53
54
55
56
57
58
59
60

1
2
3 be inferred since this would require comparison of beta-blocker doses which exhibit
4 the same degree of beta₁ antagonism as assessed by exercise heart rate
5 reduction,[70] which was not measured.
6
7

8
9 In a post hoc analysis of 2670 patients from the organized program to initiate
10 lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF), there
11 were no differences between selective and non-selective beta-blockers in terms of
12 lower mortality or re-hospitalization in patients with and without COPD.[72]
13 Carvedilol blocks both cardiac beta₁ and beta₂ receptors as well as exhibiting
14 peripheral vasodilatation due to alpha receptor blockade, which in addition to its anti-
15 oxidant activity [73] may explain its superiority verses metoprolol in heart failure in
16 one particular study, which may not have compared comparable doses.[63] Until
17 there is more convincing evidence to support the superiority of carvedilol in heart
18 failure, it would be prudent to choose a selective agent such as bisoprolol, nebivolol
19 or metoprolol due to their superior safety profile in COPD.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Long acting muscarinic antagonists such as tiotropium have been shown to obviate
35 bronchoconstriction even when using non-selective beta-blockade with propranolol in
36 asthmatic patients.[58] It is the more severe COPD patients who would in theory be
37 most at risk of beta-blocker induced bronchoconstriction. These patients would
38 usually already be taking concomitant LAMA and hence be protected from
39 bronchospasm. The relatively small degree of dose related beta₂ receptor
40 antagonism conferred for example by bisoprolol [59] would not be expected to result
41 in worsening of pulmonary function. It is also important to consider the potential
42 impact of beta₂ receptor genotype on the risk-benefit equation with beta-blockers in
43 COPD. It has been shown that asthmatic patients who possess one or two copies of
44 the arginine-16 beta₂ receptor polymorphism are more prone to propranolol induced
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 bronchoconstriction in terms of FEV₁ and airway resistance.[75] While the arginine-
4
5 16 polymorphism conferred a worse outcome on survival in patients receiving
6
7 metoprolol after an acute coronary syndrome,[76] it was not associated with survival
8
9 in HF patients treated with metoprolol or carvedilol.[77]
10

11 12 13 14 **Conclusions and the ways forward (Box 3)**

15
16 There are compelling reasons to use cardio-selective beta-blockers in patients with
17
18 COPD who have coexistent heart failure or are post myocardial infarction. Current
19
20 evidence would suggest that there remains a reticence to prescribe beta-blockers in
21
22 such patients because of a fear of adverse events, particularly worsened lung
23
24 function. Further prospective medium term safety studies are therefore required to
25
26 carefully follow effects of cardio-selective drugs on pulmonary function in patients
27
28 with more severe COPD by employing slow initial dose titration as well as evaluating
29
30 their interaction with long acting bronchodilators (ClinicalTrials.gov
31
32 Identifier:NCT01656005).
33
34
35

36
37 There is currently not sufficient evidence to advocate treatment with beta-blockers
38
39 for the prevention of exacerbations or exacerbation-related mortality. Long term
40
41 placebo controlled multicenter trials in COPD are indicated to confirm the benefits of
42
43 beta-blockers already seen on mortality and exacerbations in observational studies.
44
45 The key question to answer is whether the potential benefits of beta-blockers are
46
47 confined to those patients with known cardiovascular disease or are present in the
48
49 wider population who may have silent cardiovascular disease. Likewise, beta-
50
51 blockers are not currently indicated in COPD patients with diastolic dysfunction alone
52
53 where controlled trials are also warranted.
54
55
56
57
58
59
60

Beta-blockers are likely to be part of a more complex therapeutic jigsaw in addressing the composite risk from different cardiovascular abnormalities in COPD, and as has already been shown with heart failure there may be additive effects from drugs acting on other neuro-hormonal pathways. This includes drugs which block the renin-angiotensin system that may be particularly effective at regressing left ventricular hypertrophy.[78] Dual angiotensin/neprilysin inhibition [79] may also confer benefits by augmenting BNP levels and ameliorate the adverse effects of hypoxic pulmonary vasoconstriction.[80, 81] Anti-platelet drugs might also be beneficial for treating silent coronary artery disease in more severe COPD patients who are oxygen dependent.[42] Pulmonologists have tended to focus on drugs which act on the lung rather than the heart, because of the evidence supporting the former. Perhaps now is time to look at the lungs' next door neighbour in the chest and begin to address the unmet need of cardiac disease in COPD.

References

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasser K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco

RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380(9859): 2095-2128.

2. Lopez-Campos JL, Ruiz-Ramos M, Soriano JB. Mortality trends in chronic obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression analysis. *Lancet Respir Med* 2014; 2(1): 54-62.

3. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. *Clinicoecon Outcomes Res* 2013; 5: 235-245.

4. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. *Chest* 2015; 147(1): 31-45.

5. Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agusti A, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL, Research

- 1
2
3 AETFc. An official american thoracic society/european respiratory society
4 statement: research questions in chronic obstructive pulmonary disease. *Am J*
5
6
7 *Respir Crit Care Med* 2015: 191(7): e4-e27.
8
9
10 6. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and
11
12 cardiovascular disease. *Transl Res* 2013: 162(4): 237-251.
13
14 7. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ.
15
16 Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and
17
18 epidemiology. *Eur J Heart Fail* 2009: 11(2): 130-139.
19
20
21 8. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD
22
23 mortality: a systematic review and meta-analysis. *BMC Pulm Med* 2012: 12: 48.
24
25 9. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of
26
27 mortality and exacerbation in patients with COPD: a meta-analysis of observational
28
29 studies. *PLoS One* 2014: 9(11): e113048.
30
31
32 10. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective
33
34 beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. *Respir*
35
36 *Med* 2003: 97(10): 1094-1101.
37
38
39 11. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after
40
41 myocardial infarction: systematic review and meta regression analysis. *BMJ* 1999:
42
43 318(7200): 1730-1737.
44
45 12. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman
46
47 EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL,
48
49 Investigators RR. beta-Blocker use and clinical outcomes in stable outpatients with
50
51 and without coronary artery disease. *JAMA* 2012: 308(13): 1340-1349.
52
53
54 13. Williams MC, Murchison JT, Edwards LD, Agusti A, Bakke P, Calverley PM,
55
56 Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-

Singer R, Vestbo J, Wouters E, Yates JC, van Beek EJ, Newby DE, MacNee W, Evaluation of CLtIPSEi. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. *Thorax* 2014; 69(8): 718-723.

14. Patel AR, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. *Chest* 2012; 141(4): 851-857.

15. Patel AR, Kowlessar BS, Donaldson GC, Mackay AJ, Singh R, George SN, Garcha DS, Wedzicha JA, Hurst JR. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013; 188(9): 1091-1099.

16. McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R, O'Connor J, McAlpine L, Chalmers G, Newby DE, Clark E, Macfarlane PW, Macnee W. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. *Eur Respir J* 2012; 39(5): 1097-1103.

17. Cargill RI, Kiely DG, Lipworth BJ. Adverse effects of hypoxaemia on diastolic filling in humans. *Clin Sci (Lond)* 1995; 89(2): 165-169.

18. Kiely DG, Cargill RI, Grove A, Struthers AD, Lipworth BJ. Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. *Thorax* 1995; 50(10): 1062-1066.

19. Kiely DG, Cargill RI, Lipworth BJ. Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers. *Br J Clin Pharmacol* 1995; 40(4): 313-318.

- 1
2
3 20. Newnham DM, Wheeldon NM, Lipworth BJ, McDevitt DG. Single dosing
4 comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and
5 salbutamol in normal subjects. *Thorax* 1993; 48(6): 656-658.
6
7
8
9
10 21. Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van
11 Tassell B, Mukherjee D, Lichstein E. Benefits of beta blockers in patients with heart
12 failure and reduced ejection fraction: network meta-analysis. *BMJ* 2013; 346: f55.
13
14 22. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
15 *Lancet* 1999; 353(9146): 9-13.
16
17
18
19
20 23. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P,
21 Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL,
22 Carvedilol Prospective Randomized Cumulative Survival Study G. Effect of carvedilol
23 on the morbidity of patients with severe chronic heart failure: results of the carvedilol
24 prospective randomized cumulative survival (COPERNICUS) study. *Circulation*
25 2002; 106(17): 2194-2199.
26
27
28
29
30
31
32
33 24. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL
34 Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*
35 1999; 353(9169): 2001-2007.
36
37
38
39
40 25. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J,
41 McMurray JJ. Heart failure and chronic obstructive pulmonary disease the quandary
42 of Beta-blockers and Beta-agonists. *J Am Coll Cardiol* 2011; 57(21): 2127-2138.
43
44
45
46
47 26. Bavishi C, Chatterjee S, Ather S, Patel D, Messerli FH. Beta-blockers in heart
48 failure with preserved ejection fraction: a meta-analysis. *Heart Fail Rev* 2015; 20(2):
49 193-201.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

27. Short PM, Anderson WJ, Elder DH, Struthers AD, Lipworth BJ. Impact of Left Ventricular Hypertrophy on Survival in Chronic Obstructive Pulmonary Disease. *Lung* 2015.

28. Boussuges A, Pinet C, Molenat F, Burnet H, Ambrosi P, Badier M, Sainty JM, Orehek J. Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study. *Am J Respir Crit Care Med* 2000; 162(2 Pt 1): 670-675.

29. Funk GC, Lang I, Schenk P, Valipour A, Hartl S, Burghuber OC. Left ventricular diastolic dysfunction in patients with COPD in the presence and absence of elevated pulmonary arterial pressure. *Chest* 2008; 133(6): 1354-1359.

30. Butler J, Schrijen F, Henriquez A, Polu JM, Albert RK. Cause of the raised wedge pressure on exercise in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1988; 138(2): 350-354.

31. Smith BM, Prince MR, Hoffman EA, Bluemke DA, Liu CY, Rabinowitz D, Hueper K, Parikh MA, Gomes AS, Michos ED, Lima JA, Barr RG. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis COPD Study. *Chest* 2013; 144(4): 1143-1151.

32. Cuttica MJ, Colangelo LA, Shah SJ, Lima J, Kishi S, Arynchyn A, Jacobs DR, Jr., Thyagarajan B, Liu K, Lloyd-Jones D, Kalhan R. Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age. *Am J Respir Crit Care Med* 2015; 192(1): 76-85.

33. Alter P, van de Sand K, Nell C, Figiel JH, Greulich T, Vogelmeier CF, Koczulla AR. Airflow limitation in COPD is associated with increased left ventricular wall stress in coincident heart failure. *Respir Med* 2015.

- 1
2
3 34. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality
4 in exacerbations of chronic obstructive pulmonary disease. *Thorax* 2012; 67(11):
5 970-976.
6
7
8
9
10 35. Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M,
11 Magnussen H. Decreasing cardiac chamber sizes and associated heart dysfunction
12 in COPD: role of hyperinflation. *Chest* 2010; 138(1): 32-38.
13
14
15 36. Heindl S, Lehnert M, Criege CP, Hasenfuss G, Andreas S. Marked sympathetic
16 activation in patients with chronic respiratory failure. *Am J Respir Crit Care Med*
17 2001; 164(4): 597-601.
18
19
20 37. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta
21 blockers in treatment of chronic obstructive pulmonary disease: a retrospective
22 cohort study. *BMJ* 2011; 342: d2549.
23
24
25 38. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta
26 blockers and the risk of death in hospitalised patients with acute exacerbations of
27 COPD. *Thorax* 2008; 63(4): 301-305.
28
29
30 39. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may
31 reduce mortality and risk of exacerbations in patients with chronic obstructive
32 pulmonary disease. *Archives of internal medicine* 2010; 170(10): 880-887.
33
34
35 40. Andell P, Erlinge D, Smith JG, Sundstrom J, Lindahl B, James S, Koul S.
36 beta-blocker use and mortality in COPD patients after myocardial infarction: a
37 Swedish nationwide observational study. *J Am Heart Assoc* 2015; 4(4).
38
39
40 41. Puente-Maestu L, Calle M, Ortega-Gonzalez A, Fuster A, Gonzalez C,
41 Marquez-Martin E, Marcos-Rodriguez PJ, Calero C, Rodriguez-Hermosa JL, Malo de
42 Molina R, Aburto M, Sobradillo P, Alcazar B, Tirado-Conde G, Group G. Multicentric
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

study on the beta-blocker use and relation with exacerbations in COPD. *Respir Med* 2014; 108(5): 737-744.

42. Ekstrom MP, Hermansson AB, Strom KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013; 187(7): 715-720.

43. Bhatt SP, Wells JM, Kinney GL, Washko GR, Jr., Budoff M, Kim YI, Bailey WC, Nath H, Hokanson JE, Silverman EK, Crapo J, Dransfield MT, Investigators CO. beta-Blockers are associated with a reduction in COPD exacerbations. *Thorax* 2015.

44. von Haehling S, Schefold JC, Jankowska E, Doehner W, Springer J, Strohschein K, Genth-Zotz S, Volk HD, Poole-Wilson P, Anker SD. Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure. *PLoS One* 2009; 4(7): e6411.

45. Dunzendorfer S, Wiedermann CJ. Modulation of neutrophil migration and superoxide anion release by metoprolol. *J Mol Cell Cardiol* 2000; 32(6): 915-924.

46. Garlichs CD, Zhang H, Mugge A, Daniel WG. Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. *Eur J Clin Invest* 1999; 29(1): 12-16.

47. Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner TD, Wedzicha JA. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. *Thorax* 2001; 56(1): 30-35.

48. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, Tuvim MJ, Dickey BF, Bond RA. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. *Am J Respir Cell Mol Biol* 2008; 38(3): 256-262.

- 1
2
3 49. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomized placebo-
4 controlled trial to evaluate chronic dosing effects of propranolol in asthma. *Am J*
5
6
7 *Respir Crit Care Med* 2013; 187(12): 1308-1314.
8
- 9 50. Anderson WJ, Short PM, Williamson PA, Manoharan A, Lipworth BJ. The
10 inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-
11
12 moderate persistent asthma. *Clin Sci (Lond)* 2014; 127(11): 635-643.
13
- 14 51. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K,
15 Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY,
16
17 Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH,
18
19 Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A,
20
21 Task Force for the D, Treatment of A, Chronic Heart Failure of the European Society
22
23 of C, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-
24
25 Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C,
26
27 Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A,
28
29 Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA,
30
31 Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF,
32
33 Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis
34
35 JT, Ponikowski P, Guidelines ESCCfP. ESC guidelines for the diagnosis and
36
37 treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis
38
39 and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of
40
41 Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of
42
43 the ESC. *Eur J Heart Fail* 2012; 14(8): 803-869.
44
45
- 46 52. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes
47
48 PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R.
49
50 Global strategy for the diagnosis, management, and prevention of chronic
51
52
53
54
55
56
57
58
59
60

obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2013; 187(4): 347-365.

53. Quint JK, Herrett E, Bhaskaran K, Timmis A, Hemingway H, Wedzicha JA, Smeeth L. Effect of beta blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. *BMJ* 2013; 347: f6650.

54. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. *QJM* 2005; 98(7): 493-497.

55. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. *J Am Coll Cardiol* 2001; 37(7): 1950-1956.

56. Tavazzi L, Swedberg K, Komajda M, Bohm M, Borer JS, Lainscak M, Robertson M, Ford I, Investigators S. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. *Int J Cardiol* 2013; 170(2): 182-188.

57. Lipworth BJ, Williamson PA. Think the impossible: beta-blockers for treating asthma. *Clin Sci (Lond)* 2010; 118(2): 115-120.

58. Short PM, Anderson WJ, Williamson PA, Lipworth BJ. Effects of intravenous and oral beta-blockade in persistent asthmatics controlled on inhaled corticosteroids. *Heart* 2014; 100(3): 219-223.

59. Lipworth BJ, Irvine NA, McDevitt DG. A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. *Eur J Clin Pharmacol* 1991; 40(2): 135-139.

- 1
2
3 60. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG,
4
5 McMurray JJ. Bisoprolol in patients with heart failure and moderate to severe chronic
6
7 obstructive pulmonary disease: a randomized controlled trial. *Eur J Heart Fail* 2009:
8
9 11(7): 684-690.
10
11 61. Mainguy V, Girard D, Maltais F, Saey D, Milot J, Senechal M, Poirier P,
12
13 Provencher S. Effect of bisoprolol on respiratory function and exercise capacity in
14
15 chronic obstructive pulmonary disease. *Am J Cardiol* 2012: 110(2): 258-263.
16
17 62. Thirapatarapong W, Armstrong HF, Bartels MN. Exercise capacity and
18
19 ventilatory response during exercise in COPD patients with and without beta
20
21 blockade. *Lung* 2013: 191(5): 531-536.
22
23 63. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P,
24
25 Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag
26
27 A, Skene A, Carvedilol Or Metoprolol European Trial I. Comparison of carvedilol and
28
29 metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol
30
31 Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet* 2003:
32
33 362(9377): 7-13.
34
35 64. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human
36
37 beta1, beta2 and beta3 adrenoceptors. *Br J Pharmacol* 2005: 144(3): 317-322.
38
39 65. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman
40
41 CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients
42
43 with chronic heart failure and chronic obstructive pulmonary disease: a randomized
44
45 crossover trial. *J Am Coll Cardiol* 2010: 55(17): 1780-1787.
46
47 66. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences
48
49 between bisoprolol and carvedilol in patients with chronic heart failure and chronic
50
51
52
53
54
55
56
57
58
59
60

obstructive pulmonary disease: a randomized trial. *Respir Med* 2011; 105 Suppl 1: S44-49.

67. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. *Chest* 2005; 127(3): 818-824.

68. Bundkirchen A, Brixius K, Bolck B, Nguyen Q, Schwinger RH. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. *Eur J Pharmacol* 2003; 460(1): 19-26.

69. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta1-selective beta-blockers. *J Clin Pharm Ther* 2003; 28(3): 179-186.

70. Wheeldon NM, McDevitt DG, Lipworth BJ. Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects. *Br J Clin Pharmacol* 1992; 34(4): 337-343.

71. Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. *Drugs* 2010; 70(1): 41-56.

72. Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O'Connor CM. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). *Am J Cardiol* 2013; 111(4): 582-587.

73. DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH. beta-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. *Open Heart* 2015; 2(1): e000230.

- 1
2
3 74. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A,
4 Lerebours G, Tavazzi L, Investigators S. Ivabradine and outcomes in chronic heart
5 failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010: 376(9744):
6 875-885.
7
8
9
10
11 75. Anderson WJ, Short PM, Manoharan A, Lipworth JL, Lipworth BJ. Influence of
12 beta2-adrenoceptor 16 genotype on propranolol-induced bronchoconstriction in
13 patients with persistent asthma. *Ann Allergy Asthma Immunol* 2014: 112(5): 475-
14 476.
15
16
17
18
19 76. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-
20 adrenergic receptor genotype and survival among patients receiving beta-blocker
21 therapy after an acute coronary syndrome. *Jama* 2005: 294(12): 1526-1533.
22
23
24
25 77. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B,
26 Muhlestein JB, Donahue M, Liggett SB, Anderson JL, Kraus WE. Lack of association
27 between adrenergic receptor genotypes and survival in heart failure patients treated
28 with carvedilol or metoprolol. *J Am Coll Cardiol* 2008: 52(8): 644-651.
29
30
31
32 78. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman
33 J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and
34 eplerenone/enalapril in patients with essential hypertension and left ventricular
35 hypertrophy: the 4E-left ventricular hypertrophy study. *Circulation* 2003: 108(15):
36 1831-1838.
37
38
39
40 79. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR,
41 Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P-H,
42 Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl*
43 *J Med* 2014: 371(11): 993-1004.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

80. Cargill RI, Lipworth BJ. Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. *Br J Clin Pharmacol* 1995; 40(6): 585-590.

81. Cargill RI, Lipworth BJ. Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects. *Chest* 1996; 110(5): 1220-1225.

Potential cardiac targets for beta-blockers in COPD (Box 1)

- Improved left ventricular systolic and diastolic function
- Reduced left ventricular dilatation
- Protection against myocardial ischemia
- Reduced left ventricular mass
- Reduced heart rate
- Anti-arrhythmic effects
- Inhibition of myocyte apoptosis
- Protection against hypoxic sympathetic drive
- Protection against adverse effects of beta-agonists

Potential non-cardiac targets for beta-blockers in COPD

- Inhibition of endothelin-1 release
- Reduction in circulating pro-inflammatory cytokines
- Inhibition of neutrophil chemotaxis and respiratory burst
- Reduction in Goblet cell number and mucus release

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Prescribing of beta-blockers in COPD for cardiovascular disease (Box 2)


- Beta-1 selective antagonists including metoprolol, bisoprolol and nebivolol exhibit dose related beta-2 receptor blockade
- Carvedilol is a non-selective beta-antagonist which is more likely to cause bronchoconstriction than beta-1 selective antagonists
- Slowly titrate the dose of beta-blockers at 1-2 weekly intervals up to the usual maintenance dose
- Monitor supine and erect blood pressure, heart rate and spirometry during dose titration
- Concomitant long-acting muscarinic antagonists may obviate potential bronchoconstriction
- Symptomatic bradycardia may occur if beta-blockers are used with other rate limiting drugs such as calcium blockers (e.g. verapamil, diltiazem), ivabradine or anti-arrhythmic agents (e.g. digoxin, amiodarone, flecainide)
- Symptomatic hypotension may occur when beta-blockers are used with other vasodilator drugs (e.g. angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, alpha receptor blockers)

Key messages (Box 3)

- Cardiovascular comorbidity, including coronary artery disease and heart failure, commonly coexists in COPD due to the effects of smoking, systemic inflammation, hypoxaemia and other shared risks.
- COPD may also be associated with impaired diastolic filling due to lung hyperinflation, which may be compounded by the negative lusitropic effects of hypoxaemia and left ventricular hypertrophy.
- The main indications for beta blockers in patients with COPD are post myocardial infarction and heart failure with reduced ejection fraction. Despite clear evidence beta-blockers improve outcomes in these COPD patients they remain significantly underused due to concerns about adverse respiratory effects, even with beta-1 selective antagonists.
- Meta-analyses of retrospective studies with beta-blockers in COPD have shown pooled estimates for reductions in mortality of 28% and exacerbations of 38%.
- Initiating treatment with beta-blockers requires careful dose titration and monitoring. This may be particularly relevant for patients with COPD who are often older and have other comorbidities that increase the risk of intolerance.
- Beta-1 selective antagonists such as bisoprolol, nebivolol and metoprolol are preferred to the non-selective carvedilol as they are less likely to produce bronchoconstriction in COPD.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Long acting muscarinic antagonists, which are commonly used in COPD protect against the potential for bronchoconstriction due to dose related beta-2 receptor antagonism.
- The key unanswered question is whether beta-blockers may confer benefits on mortality and exacerbations in all patients with COPD including those with silent cardiovascular disease.



LA ↑ left atrial dilatation , LV ↓ : reduced LV filling LVH: left ventricular hypertrophy
 CAD: coronary artery disease, PoHT: pulmonary hypertension , RV ↓:reduced right ventricular filling
 RVH: right ventricular hypertrophy